**Additional File 2 – Study Assessments**

Sandeep J. Khandhar MD; Mark R. Bowling MD; Javier Flandes MD; Thomas R. Gildea MD; Kristin L. Hood, PhD; William S. Krimsky MD; Douglas J. Minnich MD; Septimiu D. Murgu MD; Michael Pritchett DO MPH; Eric M. Toloza MD PhD; Momen M. Wahidi MD; Jennifer J. Wolvers BSc; Erik E. Folch MD for the NAVIGATE Study Investigators. Electromagnetic Navigation Bronchoscopy to Access Lung Lesions in 1000 Subjects: First Results of the Prospective, Multicenter NAVIGATE Study

This content has been previously published in its current form under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>). Source: Folch EE, Bowling MR, Gildea TR, et al. Design of a prospective, multicenter, global, cohort study of electromagnetic navigation bronchoscopy. BMC Pulm Med 2016; 16: 60.

|  |
| --- |
| **Subject Demographics** |
| * Age * Sex * Ethnicity * Race |
| **Subject Medical History and Baseline Status** |
| * Prior invasive lung procedures and surgeries * Lung function and diffusing capacity * Antithrombotic medication current and prior status, including duration of any discontinuation * Subject risk factors * Pre-procedure probability of malignancy * Quality of life (EQ-5D) |
| **Lesion Characteristics** |
| * Size * Location * Presence of bronchus sign on computerized tomography (CT) * Lung zone (peripheral, middle, and proximal thirds) * Visibility on fluoroscopy (if applicable) * Positron emission tomography (PET)-positive (yes/no) * Associated lymphadenopathy * Distance to closest fissure * Distance from lesion to pleura * Preprocedure probability of malignancy (investigator assessment) |
| **Procedural Assessments** |
| * Indication for procedure * Anesthesia type * Catheter type * Procedure duration * Imaging used (fluoroscopy, PET, radial endobronchial ultrasound [EBUS]) * Ability to successfully navigate to lesion * Use of associated tools and type (e.g., access tools, biopsy forceps, cytology brush, aspiration needle) * Number of lesions biopsied * Number of lymph nodes biopsied (if applicable) * Placement of fiducial markers (if applicable), type used, indication, and status at follow-up imaging * Surgical resection, including use of dye marker, type used, and adequacy for surgical resection * Diagnosis by both cytologic rapid on-site evaluation (ROSE) and pathology * Cancer type (primary or metastatic), if applicable * Cancer stage, if applicable * Adequacy of sample for molecular testing and mutation type (if applicable) * Lymph node number, station, size, and success in obtaining sample (if applicable) * Number and type of repeat electromagnetic navigational bronchoscopy (ENB) procedures or other biopsies * Other health services (e.g., imaging, transfusion, surgery, emergency room admission, prescriptions) received during admission for index procedure * Hospital admission duration * Adverse events, action taken, relationship to device, and outcome |
| **Follow-up Assessments** |
| * Subject satisfaction (at 1-month follow-up only) * Subject quality of life (EQ-5D) at all follow-up visits * ENB Productivity and Activity Questionnaire (ENB-PAQ) at 1 month visit * All health services (e.g., imaging, transfusion, surgery, emergency room admission, prescriptions) received since last visit * All healthcare services related to lung health since index procedure (e.g., primary care and specialist visits, hospital, emergency room, oncology, radiology, pain management). * All therapeutic and diagnostic procedures and diagnoses related to lung health since last visit * Adverse events, action taken, relationship to device, and outcome |